

RECEIVED
CENTRAL FAX CENTERSerial No. 09/847,935
Reply of August 8, 2006

AUG 08 2006 D-2914

STATUS OF THE CLAIMS

Please enter the following claim set as a replacement for any previously presented claim set.

1-59. (Cancelled)

60. (Currently amended) A composition comprising:

an ion-pair complex including, in an aqueous medium, a therapeutic component comprising an adrenergic agonist, and an efficacy enhancing component, wherein the efficacy enhancing component comprises a fatty acid selected from the group consisting of lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, lignoceric acid, palmitoleic acid, oleic acid, linoleic acid, linolenic acid, derivatives and mixtures thereof, and is present in an amount greater than 0.2% (w/v) and less than about 10% (w/v) and being effective to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, each of the enhanced effects being relative to the effect obtained with the therapeutic component without the efficacy enhancing component.

61. (Previously presented) A composition of claim 60 wherein the therapeutic component comprises an alpha-2-adrenergic agonist.

62. (Previously presented) A composition of claim 61 wherein the alpha-2-adrenergic agonist includes a quinoxaline component.

Page 2 of 13.

Serial No. 09/847,935
Reply of August 8, 2006

D-2914

63. (Previously presented) A composition of claim 62 wherein the quinoxaline component is selected from the group consisting of quinoxalines, salts thereof, and mixtures thereof.

64. (Previously presented) The composition of claim 60 wherein the therapeutic component further comprises a second component selected from the group consisting of N-methyl-D-aspartate antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, and mixtures thereof.

65. (Previously presented) A composition of claim 60 which has a pH of about 7 or greater.

66. (Previously presented) A composition of claim 60 which has a pH in a range of about 7 to about 9.

67. (Cancelled)

68. (Previously presented) A composition of claim 60 which is ophthalmically acceptable.

69-71 (Cancelled)

Page 3 of 13.

Serial No. 09/847,935
Reply of August 8, 2006

D-2914

72. (Previously presented) The composition of claim 62, wherein the quinoxaline component is selected from the group consisting of (2-imidozolin-2-ylamino) quinoxalines, salts thereof, and mixtures thereof.

73. (Previously presented) The composition of claim 62, wherein the quinoxaline component is selected from the group consisting of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, salts thereof, and mixtures thereof.

74-76. (Cancelled)

77. (Previously presented) The composition of claim 73, further comprising at least one additional efficacy enhancing component selected from the group consisting saturated fatty acids and unsaturated fatty acids, and mixtures thereof.

78-86. (Cancelled)

87. (Previously presented) A composition comprising:
an ion-pair complex including, in an aqueous medium, a therapeutic component and an efficacy enhancing component, wherein the complex comprises a 3:1, 2:1, 1:1, 1:2 or 1:3 molar ratio of efficiency-enhancing component to therapeutic component, and wherein the efficacy enhancing component is selected from the group consisting of anionic polymers, fatty acids, and mixtures thereof, and is effective to enhance the movement of the therapeutic

Page 4 of 13.

Serial No. 09/847,935
Reply of August 8, 2006

D-2914

component across a lipid membrane, or a biological membrane under physiological conditions, each of said the enhanced effects being relative to the effect obtained with the therapeutic component without complexed efficacy enhancing component.

88. (Previously presented) A composition of claim 87 wherein the therapeutic component comprises an alpha-2-adrenergic agonist.

89. (Currently amended) The composition of claim 87, wherein the quinoxaline therapeutic component is selected from the group consisting of (2-imidazolin-2-ylamino) quinoxalines, salts thereof, and mixtures thereof.

90. (Currently amended) The composition of claim 89, wherein the quinoxaline ~~component~~ is selected from the group consisting of 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline, salts thereof, and mixtures thereof.